This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adhikary, D.
Right arrow Articles by Mautner, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adhikary, D.
Right arrow Articles by Mautner, J.

 Previous Article  |  Next Article 

Journal of Virology, April 2008, p. 3903-3911, Vol. 82, No. 8
0022-538X/08/$08.00+0     doi:10.1128/JVI.02227-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Standardized and Highly Efficient Expansion of Epstein-Barr Virus-Specific CD4+ T Cells by Using Virus-Like Particles{triangledown}

Dinesh Adhikary,1 Uta Behrends,1 Regina Feederle,2 Henri-Jacques Delecluse,2 and Josef Mautner1*

Clinical Cooperation Group, Department of Pediatrics, Munich University of Technology and GSF-Research Centre for Environment and Health, Munich, Germany,1 German Cancer Research Center, Department of Virus Associated Tumours, Heidelberg, Germany2

Received 14 October 2007/ Accepted 28 January 2008

Epstein-Barr virus (EBV)-specific T-cell lines generated by repeated stimulation with EBV-immortalized lymphoblastoid B-cell lines (LCL) have been successfully used to treat EBV-associated posttransplant lymphoproliferative disease (PTLD) in hematopoietic stem cell transplant recipients. However, PTLD in solid-organ transplant recipients and other EBV-associated malignancies respond less efficiently to this adoptive T-cell therapy. LCL-stimulated T-cell preparations are polyclonal and contain CD4+ and CD8+ T cells, but the composition varies greatly between lines. Because T-cell lines with higher CD4+ T-cell proportions show improved clinical efficacy, we assessed which factors might compromise the expansion of this T-cell population. Here we show that spontaneous virus production by LCL and, hence, the presentation of viral antigens varies intra- and interindividually and is further impaired by acyclovir treatment of LCL. Moreover, the stimulation of T cells with LCL grown in medium supplemented with fetal calf serum (FCS) caused the expansion of FCS-reactive CD4+ T cells, whereas human serum from EBV-seropositive donors diminished viral antigen presentation. To overcome these limitations, we used peripheral blood mononuclear cells pulsed with nontransforming virus-like particles as antigen-presenting cells. This strategy facilitated the specific and rapid expansion of EBV-specific CD4+ T cells and, thus, might contribute to the development of standardized protocols for the generation of T-cell lines with improved clinical efficacy.

* Corresponding author. Mailing address: Children's Hospital, University of Technology, Kölner Platz 1, D-80804 Munich, Germany. Phone: 49-89-7099518. Fax: 49-89-7099500. E-mail: mautner{at}gsf.de

{triangledown} Published ahead of print on 13 February 2008.

Journal of Virology, April 2008, p. 3903-3911, Vol. 82, No. 8
0022-538X/08/$08.00+0     doi:10.1128/JVI.02227-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»